Adagene Inc (ADAG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adagene Inc (ADAG) has a cash flow conversion efficiency ratio of -0.129x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.55 Million) by net assets ($35.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Adagene Inc to measure how many days the company can operate on defensive assets alone.
Adagene Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Adagene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adagene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adagene Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ARKO Petroleum Corp.
NASDAQ:APC
|
0.033x |
|
Pennar Industries Limited
NSE:PENIND
|
0.108x |
|
Partron Co. Ltd
KQ:091700
|
0.085x |
|
Eaton Vance California MBF
NYSE MKT:EVM
|
0.036x |
|
Peña Verde S.A.B
MX:PV
|
0.005x |
|
Runway Growth Finance Corp
NASDAQ:RWAY
|
0.009x |
|
Vecima Networks Inc.
TO:VCM
|
0.092x |
|
Cellectis
PA:ALCLS
|
-0.139x |
Annual Cash Flow Conversion Efficiency for Adagene Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Adagene Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Adagene Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $35.35 Million | $-15.66 Million | -0.443x | +24.65% |
| 2024-12-31 | $50.52 Million | $-29.70 Million | -0.588x | -45.77% |
| 2023-12-31 | $70.56 Million | $-28.45 Million | -0.403x | +31.07% |
| 2022-12-31 | $83.09 Million | $-48.61 Million | -0.585x | -110.98% |
| 2021-12-31 | $156.56 Million | $-43.41 Million | -0.277x | -186.89% |
| 2020-12-31 | $-89.39 Million | $-28.53 Million | 0.319x | +0.23% |
| 2019-12-31 | $-57.01 Million | $-18.15 Million | 0.318x | -8.42% |
| 2018-12-31 | $-41.03 Million | $-14.26 Million | 0.348x | -- |
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more